Actual Medicinal Product (AMP) Ondansetron 4mg tablets (Phoenix Healthcare Distribution Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
Light sensitive medicine. Store in light resistant container. Moisture sensitive medicine. Store in airtight (sealed) MCA. Manufacturer recommends storing in original container. No stability data in MCAs available.
- Provenance
-
This recommendation is based on the products ondansetron 8mg tablets (Aurobindo Pharma - Milpharm Ltd) and ondansetron 4mg and 8mg tablets (Cipla EU Ltd).
- Generic
- Ondansetron
- Formulation
- Ondansetron 4mg tablets
-
Ondansetron
-
Ondansetron 4mg tablets
-
Ondansetron 4mg tablets (Phoenix Healthcare Distribution Ltd)
-
-
Ondansetron 4mg oral lyophilisates sugar free
Ondansetron 4mg orodispersible tablets